Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden

This is an observational study in Sweden tracking how well tofacitinib (a JAK inhibitor pill) works in real-world clinical practice for people with ulcerative colitis — a chronic inflammatory bowel condition. Researchers want to understand how effective the drug is outside of clinical trials and how consistently patients take it as prescribed. **You may be eligible if...** - You are 18 years or older - You have active ulcerative colitis (confirmed by stool test or colonoscopy within 4 weeks of starting tofacitinib) - Your doctor has decided to prescribe tofacitinib as part of your normal care - You consent to having your health data collected from Sweden's IBD registry (SWIBREG) **You may NOT be eligible if...** - You are enrolled in another interventional (treatment-based) clinical trial for ulcerative colitis - You do not consent to data collection - Your doctor's treatment decision was influenced by this study (must be standard clinical practice) Talk to your doctor to see if this trial is right for you.